TrialThe Lancet. Oncology2018

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Peter D Cole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.